Providing access to quality-assured medicines is a fundamental component of strengthening health systems. Yet, the World Health Organization (WHO) estimates that 13.6% of all medicines in low- and middle-income countries (LMIC’s) may be substandard or falsified (SF) impeding patient outcomes, imposing financial burden, and contributing to antimicrobial resistance. Circulation of SF medicines also undermines trust in the health system and legitimate health care professionals. It may erode trust in the manufacturers of genuine pharmaceutical products as well as health professionals who prescribe and dispense them. Failure to address challenges in medicines quality assurance and supply risks jeopardizing progress towards universal healthcare c...
Access to quality medicines is a universal human right which featured prominently on the agenda of t...
Access to medicine remains poor and inequitable in many low- and middle-income countries (LMICs). Th...
Introduction Access to quality-assured medicines is an essential prerequisite for universal health c...
Growing burden of communicable and non-communicable diseases in sub-Saharan Africa has necessitated ...
Abstract Access to quality-assured medical products improves health and save lives. However, one thi...
Access to quality-assured medical products improves health and save lives. However, one third of the...
The disturbing emergence of substandard and fake drugs in Ghana is largely due to inadequate supervi...
Access to quality-assured medical products improves health and save lives. However, one third of the...
The benefits of local production of pharmaceuticals in Africa for local access to medicines and to e...
Abstract Background Two billion people worldwide, pre...
open access articleAccess to affordable, safe, effective, and quality-assured medicines by a patient...
Poor-quality medicines pose a significant challenge for health systems in low- to middle-income coun...
Where regulation is weak, medicine transactions can be characterised by uncertainty over the drug qu...
Much of the current debate on health care goals, medical innovation and trade rules focuses on the m...
Access to quality medicines is a universal human right which featured prominently on the agenda of t...
Access to quality medicines is a universal human right which featured prominently on the agenda of t...
Access to medicine remains poor and inequitable in many low- and middle-income countries (LMICs). Th...
Introduction Access to quality-assured medicines is an essential prerequisite for universal health c...
Growing burden of communicable and non-communicable diseases in sub-Saharan Africa has necessitated ...
Abstract Access to quality-assured medical products improves health and save lives. However, one thi...
Access to quality-assured medical products improves health and save lives. However, one third of the...
The disturbing emergence of substandard and fake drugs in Ghana is largely due to inadequate supervi...
Access to quality-assured medical products improves health and save lives. However, one third of the...
The benefits of local production of pharmaceuticals in Africa for local access to medicines and to e...
Abstract Background Two billion people worldwide, pre...
open access articleAccess to affordable, safe, effective, and quality-assured medicines by a patient...
Poor-quality medicines pose a significant challenge for health systems in low- to middle-income coun...
Where regulation is weak, medicine transactions can be characterised by uncertainty over the drug qu...
Much of the current debate on health care goals, medical innovation and trade rules focuses on the m...
Access to quality medicines is a universal human right which featured prominently on the agenda of t...
Access to quality medicines is a universal human right which featured prominently on the agenda of t...
Access to medicine remains poor and inequitable in many low- and middle-income countries (LMICs). Th...
Introduction Access to quality-assured medicines is an essential prerequisite for universal health c...